Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

Blood

Volumn 129, Issue 25, 2017, Pages 3386-3388

  García Guerrero, Estefanía ^a,c   Gogishvili, Tea ^c   Danhof, Sophia ^c   Schreder, Martin ^c   Pallaud, Celine ^b   Pérez Simón, Jose Antonio ^a   Einsele, Hermann ^c   Hudecek, Michael ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; DARATUMUMAB; PANOBINOSTAT; ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; CD38 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE; SLAMF7 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LETTER; MYELOMA; MYELOMA CELL LINE; PRIORITY JOURNAL; UPREGULATION; BIOSYNTHESIS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIPLE MYELOMA; TUMOR CELL CULTURE;

ADP-RIBOSYL CYCLASE 1; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE FAMILY; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 85021677507     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-03-770776     Document Type: Letter

References (20)

1. Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8): 754-766.
2. Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375(14): 1319-1331.
3. van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127(6): 681-695.
4. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027): 1551-1560.
5. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13): 1207-1219.
6. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1): 37-44.
7. Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7): 959-970.
8. Lemaire M, Fristedt C, Agarwal P, et al. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Clin Cancer Res. 2012;18(8): 2230-2239.
9. Xie C, Drenberg C, Edwards H, et al. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One. 2013;8(11): e79106.
10. Liu HB, Urbanavicius D, Tan P, Spencer A, Dear AE. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies. Int J Oncol. 2014;45(4): 1742-1748.
11. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia. 2010;24(10): 1760-1768.
12. Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4): 554-561.
13. Sanchez E, Shen J, Steinberg J, et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res. 2011;35(3): 373-379.
14. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006;66(11): 5781-5789.
15. Mu S, Kuroda Y, Shibayama H, et al. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/ refractory multiple myeloma. Eur J Clin Pharmacol. 2016;72(2): 153-161.
16. Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10): 2039-2049.
17. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3): 1840-1848.
18. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J. 1996;10(12): 1408-1417.
19. Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7): 621-631.
20. Richardson PG, Moreau P, Laubach JP, Maglio ME, Lonial S, San-Miguel J. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacol Res. 2017;117: 185-191.